Skip to main content
All lobbying filings

STANTON PARK GROUP

Lobbying for VERTEX PHARMACEUTICALS INCORPORATED · Global biotechnology company

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $50,000.00 income · posted Apr 20, 2026

Official filing document

 Bills named in this filing 2
 Lobbying activity 1
Health Issues

Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 1227 and S. 375

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem